GLP-1 / weight-management follow-up
Keep GLP-1 patients on the dose, between every visit.
The medication is only half the program. The other half happens in the weeks between visits — and that's where clinics lose patients.
- 01The dose ladder is a string of decision points you can't see
- 02The side effects are mostly small, frequent, and manageable — but only if someone's listening
- 03Patients may stop before the clinic sees the problem
- Model
- Clinician-supervised
- Patient app
- None — a link
- Sits with
- Your EHR
Why GLP-1 follow-up is hard.
GLP-1 / weight-management follow-up
GLP-1 follow-up matters between appointments, when tolerability, dose changes, and adherence can be hard to see. SeuSive runs check-ins on channels patients already use and routes what needs attention. AI prepares the follow-up; clinically meaningful patient-facing decisions stay with the clinic. Nothing to download.
01The dose ladder is a string of decision points you can't see
Semaglutide steps up 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, at least four weeks per step, roughly sixteen weeks to the standard maintenance dose; tirzepatide climbs from 2.5 mg in 2.5 mg increments to a 15 mg max. Every step-up is really a tolerability decision — and it happens in the weeks you don't have eyes on the patient.
02The side effects are mostly small, frequent, and manageable — but only if someone's listening
Nausea hits around 43.9% of patients on semaglutide 2.4 mg, alongside vomiting, diarrhea, constipation and abdominal pain. The reassuring part: roughly 98–99% of these GI events are non-serious and mild-to-moderate, clustering during escalation. Most resolve with smaller low-fat meals, fluids, fiber, and slower titration — not stopping. They just need a channel to surface on, and a clinician to triage the real red flags.
03Patients may stop before the clinic sees the problem
Side effects, cost, coverage, and uncertainty can interrupt treatment without a clear signal to the clinic. Structured follow-up makes those barriers visible so the team can decide the appropriate next step.
How SeuSive runs the GLP-1 loop.
- 01
Intake that maps the patient to their ladder
At the start, capture the drug, the current dose, and where the patient sits on their titration schedule.
SeuSive then plans check-ins around the natural cadence of GLP-1 care — tighter during the every-four-week step-ups, easing out as the patient stabilizes. It's a common clinic pattern, not a rigid rule, and your clinician sets it.
- 02
Companion check-ins that catch the GI complaints — and the red flags
Between visits, the companion asks clinic-configured questions about weight trend, hydration, and tolerability.
Routine responses use clinic-approved guidance; concerning responses are routed for clinician review. The software does not diagnose or change a dose.
- 03
Clinician review, then the rebooking or dose call
Everything lands in one staff queue. A clinician reviews and approves outreach, decides on a dose pause, reduction, or step-up, and gets the patient re-booked before they drift.
No autonomous prescribing, no patient lost to silence — just your follow-up loop, running under your clinic's name.
Clinician-in-the-loopA weigh-in isn't follow-up. The work is in the weeks nobody sees.
GLP-1 weight management is a chronic-disease therapy — it needs continued treatment plus real support: nutrition, resistance training, and monitoring that goes beyond the scale to GI tolerability, hydration, and lean-mass preservation as an emerging priority. SeuSive is the supervised layer that does that monitoring between visits, surfaces what your clinician needs to act on, and keeps the patient on the dose long enough for it to work. Your branding, your licence, your team in the loop.
Common questions.
Does SeuSive prescribe GLP-1 medications or adjust doses on its own?
No. SeuSive does not diagnose, prescribe, or change a dose. AI can prepare and route follow-up context, while dose changes and other clinically meaningful patient-facing decisions remain with the responsible clinic team.
How does it handle GLP-1 side effects between visits?
The companion checks in on nausea, vomiting, diarrhea, constipation, hydration, and weight trend on the patient's usual channel. Most GI complaints are mild-to-moderate and respond to first-line measures your clinic configures — smaller low-fat meals, fluids, fiber, slower titration. Genuine red flags, like severe abdominal pain, inability to keep fluids down beyond 24 hours, jaundice, bloody stool, or fever, are flagged for urgent clinician evaluation rather than answered automatically.
How does it support adherence through titration?
Scheduled check-ins can make side effects, access barriers, and missed reviews visible to the clinic. SeuSive does not guarantee adherence; it gives the responsible team clearer context for follow-up.
Do patients need to download an app?
No. Patients are reached on channels they already use — SMS, WhatsApp, or web. There's nothing to install, no login to forget, and no new habit to build. For a population where convenience is part of why people stay on therapy, removing the app barrier matters.
Is the follow-up branded as SeuSive or as our clinic?
The patient experience is clinic-branded: check-ins and follow-up use your clinic's name and approved voice. Full white-label requirements are scoped separately.
What does the monitoring track beyond weight?
Weight trend is the start, not the whole picture. Between visits SeuSive tracks GI tolerability and hydration, and supports the broader chronic-care story — nutrition and resistance training — with body composition and lean-mass preservation as an emerging monitoring priority. A meaningful share of weight lost can be lean mass, so preserving muscle is increasingly part of good GLP-1 follow-up, not just a number on the scale.
How are patient-data and clinical-safety requirements handled?
Patient-data requirements are deployment-specific. Before production patient data is used, the parties must determine the applicable privacy roles, execute any required agreements, and configure and verify tenancy, hosting and residency, retention, access controls, and enabled vendors and channels for the clinic. SeuSive does not claim blanket HIPAA or GDPR compliance or certification. The care model remains administrative and supervisory: it supports your workflow under clinician oversight and does not provide autonomous diagnosis, prescribing, or emergency services.
See the GLP-1 follow-up loop.
Twenty minutes. We'll show how supervised check-ins run through titration, how red flags escalate to your clinician, and how patients get rebooked — then you decide.